For patient-relevant outcomes, there is no convincing evidence of a superiority of rapid-acting insulin analogues compared with RHI in diabetes mellitus type 2 therapy. Rapid-acting insulin analogues have not been sufficiently investigated with regard to their potential longterm beneficial and harmful effects.